Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment
Gaurav Chatterjee
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorVishesh Dudakia
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorSitaram Ghogale
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorNilesh Deshpande
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorKarishma Girase
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorAnumeha Chaturvedi
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorDhanlaxmi Shetty
Department of Department of Cancer Cytogenetics, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorManju Senger
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorHasmukh Jain
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorBhausaheb Bagal
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorAvinash Bonda
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorSachin Punatar
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorAnant Gokarn
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorNavin Khattry
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorNikhil V. Patkar
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorSumeet Gujral
Department of Pathology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorPapagudi G. Subramanian
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorCorresponding Author
Prashant R. Tembhare
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Correspondence
Prashant R. Tembhare, Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Room 18, Hematopathology Laboratory, CCE Building, ACTREC, Sector 22, Navi Mumbai 410210, India.
Email: [email protected]
Search for more papers by this authorGaurav Chatterjee
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorVishesh Dudakia
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorSitaram Ghogale
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorNilesh Deshpande
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorKarishma Girase
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorAnumeha Chaturvedi
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorDhanlaxmi Shetty
Department of Department of Cancer Cytogenetics, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorManju Senger
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorHasmukh Jain
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorBhausaheb Bagal
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorAvinash Bonda
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorSachin Punatar
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorAnant Gokarn
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorNavin Khattry
Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorNikhil V. Patkar
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorSumeet Gujral
Department of Pathology, Tata Memorial Center, HBNI University, Mumbai, India
Search for more papers by this authorPapagudi G. Subramanian
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Search for more papers by this authorCorresponding Author
Prashant R. Tembhare
Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
Correspondence
Prashant R. Tembhare, Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Room 18, Hematopathology Laboratory, CCE Building, ACTREC, Sector 22, Navi Mumbai 410210, India.
Email: [email protected]
Search for more papers by this authorAbstract
Introduction
Many new markers are being evaluated to increase the sensitivity and applicability of multicolor flow cytometry (MFC)-based measurable residual disease (MRD) monitoring. However, most of the studies are limited to childhood B-cell lymphoblastic leukemia/lymphoma (B-ALL), and reports in adult B-ALL are extremely scarce and limited to small cohorts. We studied the expression of CD304/neuropilin-1 in a large cohort of adult B-ALL patients and evaluated its practical utility in MFC-based MRD analysis.
Methods
CD304 was studied in blasts from adult B-ALL patients and normal precursor B cells (NPBC) from non-B-ALL bone marrow samples using MFC. CD304 expression intensity and pattern were studied with normalized-mean fluorescent intensity (nMFI) and coefficient of variation of immunofluorescence (CVIF), respectively. MFC-based MRD was performed at end of induction (EOI; day-35), end of consolidation (EOC; day 78-80), and subsequent follow-up (SFU) time points.
Results
CD304 was positive in 120/214(56.07%) and was significantly associated with BCR-ABL1 fusion (P = .001). EOI-MRD and EOC-MRD were positive in 129/214(60.3%) and 50/81(61.72%), respectively. CD304 was positive in a significant percentage of EOI (48%, 62/129) and EOC (52%, 26/50) MRD-positive B-ALL samples. Its expression was retained, lost, and gained in 73.7%, 26.3%, and 11.3% of EOI-MRD and 85.7%, 14.3%, and none of EOC-MRD samples, respectively. Low-level MRD (<0.01%) was detectable in 34 of all (EOI + EOC + SFU = 189) MRD-positive samples, and CD304 was found useful in 50% of these samples.
Conclusion
CD304 is commonly expressed in adult B-ALL and clearly distinguish B-ALL blasts from normal precursor B cells. It is a stable MRD marker and distinctly useful in the detection of MFC-based MRD monitoring, especially in high-sensitivity MRD assay.
CONFLICT OF INTEREST
The authors have no competing interests.
DISCLOSURE
Co-author Nikhil V Patkar is supported by the Wellcome Trust-DBT/India Alliance through an Intermediate Fellowship for Clinicians and Public Health Researchers.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| ijlh13456-sup-0001-Supinfo.docxWord document, 1.3 MB | Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Dworzak MN, Gaipa G, Ratei R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom. 2008; 74(6): 331-340.
- 2O'Connor D, Enshaei A, Bartram J, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018; 36(1): 34-43.
- 3Pui CH, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015; 16(4): 465-474.
- 4van der Velden VH, Noordijk R, Brussee M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukaemia: impact of primer characteristics and size of junctional regions. Br J Haematol. 2014; 164(3): 451-453.
- 5van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015; 125(26): 3996-4009.
- 6Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011; 117(23): 6267-6276.
- 7Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016; 90(1): 47-53.
- 8Tembhare PR, Subramanian Pg PG, Ghogale S, et al. A high-sensitivity 10-color flow cytometric minimal residual disease assay in b-lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: a study of 622 patients. Cytometry B Clin Cytom. 2020; 98(1): 57-67.
- 9Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017; 129(3): 347-357.
- 10Sędek Ł, Bulsa J, Sonsala A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? Cytometry B Clin Cytom. 2014; 86(5): 329-339.
- 11Dworzak MN, Fritsch G, Fleischer C, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia. 1997; 11(8): 1266-1273.
- 12van Lochem EG, Wiegers YM, van den Beemd R, Hahlen K, van Dongen JJ, Hooijkaas H. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia. 2000; 14(4): 688-695.
- 13van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004; 60(1): 1-13.
- 14Sędek Ł, Theunissen P, Sobral da Costa E, et al. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. J Immunol Methods. 2019; 475: 112429.
- 15Tembhare PR, Ghogale S, Ghatwai N, et al. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000. Cytometry B Clin Cytom. 2018; 94(1): 100-111.
- 16Weng XQ, Shen Y, Sheng Y, et al. Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. Blood cancer journal. 2013; 3(8):e133.
- 17Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom. 2010; 78(3): 147-153.
- 18Gaipa G, Basso G, Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005; 19(1): 49-56.
- 19Theunissen PMJ, Sedek L, De Haas V, et al. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. Br J Haematol. 2017; 178(2): 257-266.
- 20Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematology. 2017; 2017(1): 13-21.
- 21Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020; 395(10230): 1146-1162.
- 22Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(4): 386-391.
- 23Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011; 8(7): 417-424.
- 24Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000; 165(11): 6037-6046.
- 25Karjalainen K, Jaalouk DE, Bueso-Ramos CE, et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011; 117(3): 920-927.
- 26Kawakami T, Tokunaga T, Hatanaka H, et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer. 2002; 95(10): 2196-2201.
- 27Lu L, Zhang L, Xiao Z, Lu S, Yang R, Han ZC. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leukemia & lymphoma. 2008; 49(2): 331-338.
- 28Naik A, Al-Yahyaee A, Abdullah N, et al. Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells. BMC Cancer. 2018; 18(1): 533.
- 29Abaza HM, Alfeky MAA, Eissa DS, Abdel Fattah MF, Annaka LM, Ebeid FS. Neuropilin-1/cd304 expression by flow cytometry in pediatric precursor B-acute lymphoblastic leukemia: a minimal residual disease and potential prognostic marker. J Pediatr Hematol Oncol. 2018; 40(3): 200–207.
- 30Yang ZG. The neuropilin-1 ligand, Sema3A, acts as a tumor suppressor in the pathogenesis of acute leukemia. Mol Carcinog. 2019; 302(7): 1127-1135.
- 31Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24(2): 265-284.
- 32Tembhare P, Badrinath Y, Ghogale S, et al. A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry Part A. 2016; 89(3): 281-291.
- 33Tembhare P, Badrinath Y, Ghogale S, Subramanian PG. Method for DNA Ploidy Analysis Along with Immunophenotyping for Rare Populations in a Sample using FxCycle Violet. Curr Protoc Cytom. 2017; 80(1): 6.38.1-6.38.15.
- 34Gudapati P, Khanka T, Chatterjee G, et al. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2020. 98(4): 328–335.
- 35Bassan R, Brüggemann M, Radcliffe H-S, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019; 104(10): 2028-2039.
- 36Pigneux A, Montesinos P, Cong Z, et al. Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. BMC Cancer. 2018; 18(1): 1100.
- 37Mirkowska P, Hofmann A, Sedek L, et al. Leukemia surfaceome analysis reveals new disease-associated features. Blood. 2013; 121(25): e149-e159.
- 38Solly F, Angelot F, Garand R, et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A. 2012; 81(1): 17-24.
Citing Literature
